FIBROGEN INC - COMMON

0,3136

19-мая-25 13:45:00

15 мин. задержка

Акции

+0,0076

+2,48%

Сегодняшний диапазон

0,3050 - 0,3199

ISIN

N/A

Источник

NASDAQ

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

03 сен 2024 09:45:29 Источник NetDania Notify
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

06 авг 2024 13:05:02 Источник Nasdaq GlobeNewswire
FibroGen to Report Second Quarter 2024 Financial Results

30 июл 2024 13:07:00 Источник Nasdaq GlobeNewswire
FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update

30 июл 2024 13:05:00 Источник Nasdaq GlobeNewswire
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

18 июн 2024 05:00:00 Источник Nasdaq GlobeNewswire
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

03 июн 2024 13:05:00 Источник Nasdaq GlobeNewswire
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

03 июн 2024 13:02:00 Источник Nasdaq GlobeNewswire
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

23 май 2024 14:05:00 Источник Nasdaq GlobeNewswire
FibroGen to Participate in Upcoming Investor Conferences

07 май 2024 04:00:01 Источник Nasdaq GlobeNewswire
FibroGen Reports First Quarter 2024 Financial Results

06 май 2024 13:02:00 Источник Nasdaq GlobeNewswire
FibroGen to Report First Quarter 2024 Financial Results

29 апр 2024 04:00:00 Источник Nasdaq GlobeNewswire
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

24 апр 2024 13:02:00 Источник Nasdaq GlobeNewswire
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

02 апр 2024 14:46:47 Источник Nasdaq GlobeNewswire
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

26 мар 2024 04:00:00 Источник Nasdaq GlobeNewswire
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

11 мар 2024 04:00:00 Источник Nasdaq GlobeNewswire
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

26 фев 2024 13:06:00 Источник Nasdaq GlobeNewswire
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

26 фев 2024 13:05:00 Источник Nasdaq GlobeNewswire
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

20 фев 2024 04:00:00 Источник Nasdaq GlobeNewswire
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

05 фев 2024 04:00:00 Источник Nasdaq GlobeNewswire
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

25 янв 2024 04:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.